Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlierberghe, Jörg Trojan, Frank T. Kolligs, Alan Weiss, Steven Miles, Antonio Gasbarrini, Monica Lencioni, Luca Cicalese, Morris Sherman, Cesare Gridelli, Peter Buggisch, Guido Gerken, Roland M. Schmid, Corrado BoniNicola Personeni, Ziad Hassoun, Giovanni Abbadessa, Brian Schwartz, Reinhard Von Roemeling, Maria E. Lamar, Yinpu Chen, Camillo Porta

Research output: Contribution to journalArticlepeer-review

504 Scopus citations

Fingerprint

Dive into the research topics of 'Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science